The Technical Analyst
PainReform Ltd. [PRFX]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
PainReform Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.08% $0.839
/ 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.08 mill |
| EPS: | -7.14 |
| P/E: | -0.120 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 2.47 mill |
| Avg Daily Volume: | 0.142 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.120 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.690 - 0.988 ( +/- 17.76%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.839
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.839
Forecast 2: 16:00 - $0.839
Forecast 3: 16:00 - $0.839
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.839 (-2.08% ) |
| Volume | 0.0119 mill |
| Avg. Vol. | 0.142 mill |
| % of Avg. Vol | 8.39 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRFX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PRFX
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-04-18 14:19:00 - Press Release
Painreform Announces Closing Of $4 Million Public Offering
Tel aviv, israel, april 18, 2024 (globe newswire) -- painreform ltd. (nasdaq: prfx) (“painreform” or the “company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,000,000 of the company's ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares at a combined public offering price of $0.80 per share (or per ordinary share equivalent) and accompanying warrant. the warrants have an exercise price of $0.80 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance.
2024-04-09 09:00:00 - Press Release
Painreform's Non-opiate Topical Treatment For Post-surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
Tel aviv, israel, april 09, 2024 (globe newswire) -- painreform ltd. (nasdaq: prfx) ("painreform" or the "company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced groundbreaking results from new studies demonstrating the superior in-vitro release (ivr) rates of prf-110 compared to the industry leader for topical post-surgical pain management products. these findings underscore painreform's commitment to advancing non-opiate pain relief options and mark a significant milestone in the development of long-lasting pain management solutions.
2024-04-02 08:30:00 - Press Release
Painreform Reaches 50% Enrollment In The Second Part Of Its Phase 3 Clinical Trial Of Prf-110 In Bunionectomy
Tel aviv, israel, april 02, 2024 (globe newswire) -- painreform ltd. (nasdaq: prfx) ("painreform" or the "company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has reached the 50% enrollment target for the second part of phase 3 clinical trial of prf-110 in bunionectomy.
2024-03-01 08:00:00 - Press Release
Painreform Provides Year-end Business Update
Reports continued enrollment in the second part of the phase 3 clinical trial in bunionectomy
2024-01-22 08:30:00 - Press Release
Painreform To Present At The Microcap Conference In Atlantic City
Tel aviv, israel--(newsfile corp. - january 22, 2024) - painreform ltd. (nasdaq: prfx) ("painreform" or the "company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at the microcap conference which is being held on january 30 - february 1, 2024 at caesars atlantic city hotel & casino in atlantic city, nj.
Latest News
2024-01-22 08:30:00 - GlobeNewsWire
PainReform to Present at the Microcap Conference in Atlantic City
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.
2023-09-05 08:30:00 - GlobeNewsWire
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will be attending the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
2023-07-20 07:42:37 - InvestorPlace
Why Is PainReform (PRFX) Stock Up 38% Today?
PainReform (NASDAQ: PRFX ) stock is rallying on Thursday after the pharmaceutical company regained compliance with Nasdaq listing requirements. According to the company's press release, it was sent notice of it regaining compliance on July 18.
2023-07-14 14:15:15 - InvestorPlace
PRFX Stock: The $2.7 Million Reason PainReform Is Up 100% Today
In the world of biotech stocks, one company that's generating big buzz today is PainReform (NASDAQ: PRFX ). The Israeli clinical-stage pharmaceutical company has seen its stock price absolutely skyrocket.
2023-07-12 09:34:42 - InvestorPlace
Why Is PainReform (PRFX) Stock Down 40% Today?
PainReform (NASDAQ: PRFX ) stock is falling on Wednesday after the company announced a concurrent registered direct offering and private placement. The registered direct offering has PainReform agreeing to sell 301,230 shares of PRFX stock at a price of $9 per share.
2023-06-15 08:30:00 - GlobeNewsWire
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st
TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the Maxim Group Virtual Healthcare Conference, hosted by M-Vest, which is being held June 20-22, 2023.
2023-02-08 07:54:59 - InvestorPlace
Why Is PainReform (PRFX) Stock Up 48% Today?
PainReform (NASDAQ: PRFX ) stock is rocketing higher on Wednesday following an update on its delisting ordeal. A press release confirms that the company has received a letter from The Nasdaq Stock Market.
2022-09-01 08:00:00 - GlobeNewsWire
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
TEL AVIV, Israel, Sept. 01, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.
2022-03-21 09:25:00 - GlobeNewsWire
PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th
TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
2021-11-22 11:58:36 - InvestorPlace
PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today
PainReform (PRFX) stock is on the move Monday with heavy trading despite a lack of news coming from the medical device company. The post PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today appeared first on InvestorPlace.